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Шизофренијата е поврзана со зголемен ризик од кардио-метаболички морбидитет и морта-
литет. Метаболичкот синдром (МС) e релевантен предиктор за морбидитет и морталитет на 
кардиоваскуларните заболувања, исто така, се покажа дека е поприсутен кај пациенти со ши-
зофренија. Цел на ова истражување беше да ја утврдиме преваленцијата на МС во примерок од 
пациенти со шизофренија во Центарот за ментално здравје - „Пролет“, Психијатриска болница 
- Скопје и потенцијалните ризик фактори поврзани со него. Материјали и методи: примерокот 
се состои од 50 пациенти со шизофренија.  Кај сите пациенти е земена венска крв за да се од-
реди нивото на холестерол HDL, триглицериди и гликоза, измерена е телесна тежина, телесна 
висина и обемот на половината. МС е дефиниран според критериумите за Национална програма 
за холестеролска програма за возрасни третман - панели III (NCEP ATP III). Резултати: Превален-
цијата на МС кај пациенти со шизофренија изнесуваше 46,0%. Се покажа дека зголемувањето на 
индексот на телесна маса (BMI) е значително поврзано со преваленцијата на МС. Заклучок: Оваа 
студија покажала висока преваленција на МС кај пациенти со шизофренија и дека BMI може да 
биде фактор на ризик во развојот на МС. Оваа информација е клинички релевантна бидејќи BMI 
рутински се мери во психијатриска пракса и може да се користи за следење на развојот на МС 
кај пациентите со шизофренија.
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Schizophrenia has been associated with an increased risk of cardio-metabolic morbidity and 
mortality. Metabolic syndrome (MS), as a reliable predictor of cardiovascular morbidity and 
mortality, has also been shown to be more prevalent in patients with schizophrenia. In this study, 
we investigated the prevalence of  MS in a sample of patients with schizophrenia in the Center for 
Mental Health – “Prolet”, Psychiatric Hospital -Skopje, and the potential risk factors associated with 
it. Materials and methods: 50 patients with schizophrenia were recruited. All subjects provided a 
fasted sample of venous blood to measure high-density lipoprotein cholesterol (HDL-C), triglycerides 
and glucose levels. Weight, height and waist circumference were measured. Metabolic syndrome 
was defined according to the National Cholesterol Education Program Adult Tretmant Panel III 
(NCEP ATD III) criteria. Results: The prevalence of MS in patients with schizophrenia was 46.0%. 
Increasing body mass index (BMI) was identified to be significantly associated with the prevalence of 
MS. Conclusion: This study found a high prevalence of MS in patients with schizophrenia, and that 
BMI might be a risk factor in the development of MS. This information is clinically relevant as BMI 
is routinely measured in psychiatric practice today, and could be used to monitor for development 
of MS in schizophrenia.
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Introduction
Schizophrenia has been linked to metabol-
ic disturbances such as obesity, dyslipidae-
mia and hyperglycemia1-2. It has also been 
associated with a more than 3-fold increase 
in mortality associated with cardiovascular 
causes2-3. This increase in cardio-metabol-
ic morbidity and mortality might be due 
to several factors such as inherent genetic 
vulnerability or environmental exposures 
such as smoking, sedentary lifestyle, anti-
psychotic medication and gaps in health-
care access4-5. In comparison with general 
population, mortality among patients with 
schizophrenia is 2-3 times higher6-8 and life 
expectancy is 20-25% lower9. In addition to 
high incidence of suicides, the cited studies 
revealed high cardiovascular and type 2 di-
abetes associated mortality of schizophren-
ic patients6-8. One of the main reasons of 
elevated cardiovascular and type 2 diabe-
tes risks in patients with schizophrenia 
can be the high prevalence of obesity and 
metabolic syndrome among that people. 
Thus, according to studies conducted in 
USA, Canada and several Western Europe-
an countries, frequency of metabolic syn-
drome (MS) in schizophrenic patients is 1.5-
2 times higher than in general population 
or mental healthy people 10-14. MS is highly 
prevalent in patients with schizophrenia 
with reported prevalence that ranges from 
10.1% to 69.3%15-22.  MS was reported in 
42.4% of patients with schizoaffective dis-
order, in 24.6–50% of bipolar patients, and 
in 12–36% of the patients with recurrent 
depression23,24. Heiskanen et al found that 
the frequency of metabolic syndrome was 
2–4 times higher in a group of people with 
schizophrenia, treated with both atypical 
and typical neuroleptics, than in an appro-
priate reference population12.
Currently, there are at least 7 different clas-
sification criteria for MS developed by vari-
ous expert panels World Health  Organiza-
tion (WHO); The  European Group for the 
Study  of  Insulin Resistance  (EGIR); The 
National Cholesterol Education  Program 
Adult  Treatment  Panel  III (NCEP  ATD 
III); The  American Association  of Clinical 
Endocrinology; The International  Diabetes 
Federation  (IDF); The American Heart  As-
sociation  National  Heart, Lung  and Blood 
Institute  (AHA]NHLB); A Joint  Interium 
Statement25.
Meanwhile the prevalence of MS among 
patients with schizophrenia in Macedonia 
has been
never assessed. Therefore the present 
study was performed in order to display MS 
frequencies (prevalence) in patients with 
schizophrenia, examined in the Center for 
Mental Health – “Prolet”, Psychiatric Hos-
pital –Skopje.
Materials and Methods
This is a cross sectional study conducted 
from August 2018 until December 2018. 
This study was conducted at the Center 
for Mental Health – “Prolet”, Psychiatric 
Hospital –Skopje.  50 patients with diag-
nosis of schizophrenia (ICD-10) were en-
rolled. We included data from 50 patients, 
36(72.0%) males and 14(28.0%) females). All 
selected patients received antipsychotic 
drugs, and 49.7% of them – atypical anti-
psychotics (clozapine, olanzapine, risper-
idone). The antipsychotic use patterns 
were recorded by the types and number 
of administered antipsychotic drugs. As 
clozapine and olanzapine have the high-
est potential to cause metabolic abnor-
malities26-29 and weight gain28, we classi-
fied the types of antipsychotic drugs into 
a clozapine/olanzapine group (yes or no). 
The number of antipsychotics used was 
categorized as monotherapy, currently 
using only one kind of antipsychotic drug, 
and combination, currently using more 
than one kind of antipsychotic. Patients 
aged 30 and above were enrolled into the 
study. 
Arterial blood pressure, height, weight, 
and waist circumference were measured. 
Waist circumference was measured in 
the standing position. Subjects were seat-
ed when blood pressure was measured. 
Body mass index (BMI) was calculated ac-
cording to Kettle’s formula: BMI (kg/m2) 
= weight (kg)/height2 (m2). BMI was fur-
ther categorized into underweight (BMI 
<18.5 kg/m2), normal (BMI 18.5 to 24.9 kg/
m2), overweight (25.0 to 29.9 kg/m2) and 
obesity (BMI ≥30 kg/m2) according to the 
World Health Organization (WHO) public 
health action. Duration of illness for pa-
tients with schizophrenia was defined as 
the duration from onset of first psychotic 
symptom to the date of recruitment. 
Patients were fasted for 12 h before the 
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venous blood was collected for determi-
nation of laboratory parameters and plas-
ma glucose, total cholesterol, high den-
sity lipoprotein cholesterol (HDL-C), and 
triglycerides levels were measured.
We adopted the National Cholesterol Ed-
ucation Program Adult Treatment Panel 
III (NCEP ATPIII) criteria for metabolic 
syndrome in our study. This criterion in-
cluded elevated triglycerides (≥ 1.7 mmol/l 
or on drug treatment for elevated tri-
glycerides), reduced HDL-C(<=1.03mmol/l 
in males <=1.29 mmol /l in females or on 
drug treatment for reduced HDL-C), ele-
vated blood pressure (≥130 mmHg systol-
ic blood pressure or ≥85 mmHg diastol-
ic blood pressure), and elevated fasting 
glucose (≥ 6.1mmol / l). We used waist 
circumference cut-offs of >=102 cm for 
males and ≥88 cm for females. Individu-
als are considered to suffer from meta-
bolic syndrome if they fulfilled at least 3 
of the above mentioned criteria.
Descriptive statistics for all study vari-
ables were computed. These descriptive 
statistics included frequencies and per-
centages for all categorical variables in 
addition to means, standard deviations 
and ranges for all normally distributed 
continuous. In statistical analysis we ap-
plied for the relative parameters (e.g. %) 
-the chi-squared test for categorical vari-
ables and Fisher’s exact test in the case 
of independent groups. We estimate the 
odds ratio (OR) of MS in patients with 
schizophrenia, the presence of MS was 
used as the dependent categorical vari-
able. The similar approach was used to 
identify factors associated with MS in 
the patient sample. We used Mann-Whit-
ney U test to determine statistically sig-
nificant differences in numerical series. 
The group differences were assumed to 
be statistically significant at p value less 
than 0.05.
Results
Во оваа студија беа вклучени 100 A total 
of 50 patients diagnosed with schizophre-
nia were recruited for this study. The in-
vestigation group had a higher proportion 
of males- 72.0% and females-18.0%.  Mean 
age of the patients was 48.1 ± 9.3 years. All 
of them were from urban residence. Ta-
ble 1 shows the demographics and meta-
bolic characteristics of the study sample, 
the general characteristics of the sample. 
The group had a higher proportion of 
males, smokers, low socioeconomic level, 
and metabolic disturbances such as obe-
sity, hypertension, hypertriglyceridaemia 
and fasting hyperglycaemia. Olanzapine/
Clozapine was received by 70.0% of pa-
tients and 54.0% of patients were on com-
bination therapy.
ATD III, and the data analysis, MS is reg-
istered in 18 (36.0%) patients, and not 32 
(64.0%). The prevalence of MS in the group 
(total sample) is 36.0%. Female patients 
had higher MS prevalence than male pa-
tients, female sex increases the risk for MS 
(tab 10.
Those with MS were significantly older 
with a mean age of 45.1 years compared 
with those without MS with a mean age of 
39.3 years, age over 50 years increases the 
risk for MS.
More smokers and higher BMI were noted 
in patients with MS. Those with MS had a 
significantly higher BMI compared with 
those without MS, with the mean BMI at 
31.8±3.3 kg/m2 and 24.5±2.2kg/m2 respec-
tively (P <0.00). There was a trend to show 
that increasing BMI was associated with 
higher risk for MS in patients. There were 
a significantly higher proportion of smok-
ers in the group. The prevalence of MS was 
found to be significantly associated with 
patients who smoked with an unadjusted 
OR 6.90 (1.04-76.042) compared with pa-
tients who did not smoke. Low socioeco-
nomic level increases the risk for MS for 
ten times. There were no differences in 
duration of illness. According to the Odds 
Ratio(OR) familial history (registration of 
diseases in the family-cardiovascular, HTA 
and diabetes) increases the chance for MS 
four times. There were no differences of 
family history of psychiatric disorders. The 
average waist circumference of patients 
with MS is higher and it is 103.6 ± 9.2 cm, 
and in the group without MS it is 84.9 ± 
7.6 cm, the difference is statistically signif-
icant for p <0.05 (p = 0.00). The mean value 
of systolic blood pressure in patients with 
MS is higher and was 151.1 ± 9.3mmHg, 
and in the group without MS it was 126.2 
± 9.6mmHg., the difference is statistically 
significant for p <0.05 (p = 0.00) .The aver-
age value of diastolic blood pressure in pa-
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Table 1.  Characteristics of Study Subjects
tients with MS was higher and is 91.0 ± 4.7 
mmHg, and in the group without MS it was 
76.1 ± 6.8 mmHg, the difference was statis-
tically significant for p <0.05 (p = 0.00). The 
average triglyceride value in patients with 
MS was higher and was 2.5 ± 0.8 mmol/l 
(higher than ≥1.7mmol/l of the predicted 
value with NCEP ATD III), and in the group 
without MS it was 1.3 ± 0.3mmol/l, the dif-
ference was statistically significant for p 
<0.05 (p = 0.00). The average glycemic val-
ue in patients with MS was higher and was 
6.5 ± 0.6mmol/l (higher than≥ 6.1mmol/l 
of the predicted value with NCEP ATD III), 
and in the group without MS it was 4.9 ± 
0.4mmol/l, the difference was statistical-
ly significant for p <0.05 (p = 0.00). The 
mean HDL of subjects with MS was lower 
and was 1.1 ± 0.2 mmol/l, and in the group 
without MS it was1.4 ± 0.2 mmol/l (tab 2).
patients N=50 p value
Age in years, mean (SD) 48.1 ± 9.3
Gender, n (%)
Male 36(72.0)
0.0000
Female 14(18.0)
Smoking status, n (%)
Non-smokers 12(24.0)
0.0000
smokers 38(76.0)
Body Mass Index in kg/m2, n (%)
normal  18.5 to 24.9 8(16.0)
0.0001; 0.0263overweight 25.0 to 29.9 15(30.0)
obesity  ≥30 27(54.0)
Socioeconomic level, n (%)
low 37(74.0)
0.0000
moderate 13(26.0)
Family history of psychiatric disorders, n (%)
yes 27(54.0)
0.4237
no 23(46.0)
Family history of DM, of cardiac diseases, of cerebrovascular stroke, n (%)
yes 20(40.0)
0.0455
no 30(60.0)
Еmployed, n (%)
unemployed 44(88.0)
0.0000
employed 6 (12.0)
Duration of psychiatric illness , mean (SD) 15.8 ± 9.3
Elevated waist circumference, n (%)
yes 32(64.0)
0.0051
no 18(36.0)
Olanzapine/Clozapine, n (%)
yes 35(70.0)
0.0001
no 15(30.0)
Drug regimen, n (%)
Monotherapy 23(46.0)
0.4237
Combination therapy 27(54.0)
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Table 2.  Characteristics of Patients with and without MS and non-Adjusted Risk of  
  Schizophrenia on MS
Elevated blood pressure, n (%)
yes 31(62.0)
0.0164
no 19(38.0)
Elevated fasting glucose, n (%)
yes 36(72.0)
0.0001
no 14(28.0)
Reduced HDL-C, n (%)
yes 28(56.0) 0.2301
no 22(44.0)
with MS/18 without MS/32
x2/ unadjusted OR 
(95% CI)
Gender, n (%)
Female 9(50.0) 5(15.6) 6.75,p=0.000
5.4(1.43-20.38)Male 9(50.0.0) 27(84.4)
Age in years, n (%)
>50 16(88.9) 17(53.1) 6.56,p=0.010
7.05(1.38-35.87)<50 2(11.1) 15(46.9)
BMI, n (%)
≥30 14(77.8) 13(40.6) 6.40,p=0.011
5.11(1.37-19.07)<30 4(22.2) 19(59.46)
Socioeconomic level, n (%)
low 17(94.4) 20(62.5) 6.11,p=0.013
10.20(1.20-86.69)moderate 1(5.6) 12(47.5)
Smoking status, n (%)
Non-smokers 17(94.4) 21(65.6) 5.24,p=0.022
6.90(1.04-76.042)smokers 1(5.6) 11(34.4)
Duration of illness in years, mean (SD) 13.5 ±7.15 11.0 ±7.06 p= 0.0816
Family history of DM, of cardiac diseases, of cerebrovascular stroke, n (%)
yes 11(61.1) 9(28.1) 5.22,p=0.022
4.015(1.18-13.62)no 7(38.9) 23(71.9)
waist circumference, mean (SD) 103.6±9.2 84.9±7.6 p=0.00
systolic blood pressure, mean (SD) 151.1±9.3mmHg 126.2±9.6mmHg p=0.00
diastolic blood pressure, mean (SD) 91.0±4.7mmHg 76.1±6.8mmHg p=0.00
triglycerides, mean (SD) 2.5±0.8mmol/l 1.3±0.3mmol/l p=0.00
glucose, mean (SD) 6.5±0.6 mmol/l 4.9±0.4 mmol/l p=0.00
HDL-C, mean (SD) 1.1±0.2 mmol/l 1.4±0.2 mmol/l p=0.00
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Discussion
Our investigation revealed that patients 
with schizophrenia had significantly 
higher frequency of MS and some of 
its symptoms. Obtained results are in 
accordance with similar observations 
in studies conducted in the USA, 
Canada and some countries in Western 
Europe6,10-11,13,25,30. MS was more prevalent 
in males. Thus, according to our study 
the presence of schizophrenia has a 
greater contribution on development 
of MS in males than in females and 
especially in persons at the age above 
50 years. Meanwhile, some studies had 
shown that MS frequency increases 
in patients with schizophrenia 
independently of age and gender10, 13,16. 
The reasons of such discrepancies 
between results of our and other studies 
are not currently known. We did not find 
a relationship between the presence 
of MS and types of antipsychotic drug. 
The relationship between antipsychotic 
drugs and risk of developing MS has 
remained divergent in the literature14,16, 
35, 36. Observed metabolic disorders in 
schizophrenic patients can be explained 
by treatment of those persons with 
antipsychotic drugs. It was shown that 
antipsychotic medication, especially 
treatment with atypical antipsychotics, 
such as clozapine and olanzapine, 
leads to weight gain, elevation of 
insulin and atherogenicity of plasma 
lipids29, 30-31. All schizophrenic patients 
in our study received antipsychotic 
medication, it’s difficult to evaluate 
the impact of this treatment on 
development of MS. Besides, some 
authors describe elevation of visceral 
adiposity and insulin resistance in first-
episode schizophrenic patients, who 
haven’t received earlier antipsychotic 
drug therapy32. In recent years, it has 
become apparent that in patients with 
schizophrenia particular antipsychotic 
agents (AP) can have negative impact on 
some of the modifiable MS risk factors33,34. 
The differential effects of various AP 
on weight are well described with 
clozapine and olanzapine associated 
with the highest weight gain5. It is well 
known that people with schizophrenia 
are especially prone to stress and 
depression disorders. Therefore, 
metabolic disorders in these subjects 
can also be due to hyperproduction 
of simpatico-adrenal hormones. Our 
study showed that female patients had 
higher risk of having MS, which is a 
common finding in previous studies13, 
19, 35-38. Increasing BMI was associated 
with increased prevalence of MS, 
while smoking was not. Our finding 
that BMI is associated with MS has 
important clinical relevance. BMI is 
an easily obtainable measurement and 
is routinely measured in most clinical 
practices. It might inform clinicians 
of the potential risk of MS and the 
consequent risks of cardiovascular 
morbidity and mortality. Therefore, BMI 
could be a useful surrogate to screen 
and monitor for the development of MS. 
The meta analyze made by Mitchell A. 
et al findings demonstrate that MS rates 
are increasing with older age35.
Conclusion
Present findings strongly support the 
notion that patients with schizophrenia 
should be considered as a high-risk 
group. The patients with schizophrenia 
should receive regular monitoring and 
adequate treatment of cardio-metabolic 
risk factors. The high prevalence of 
the metabolic syndrome in the present 
study has several clinical implications:
1. There is a crucial need to develop 
methods, including physical activity 
and nutrition, to control metabolic 
abnormalities among schizophrenic 
patients. 
2. The education and training are 
needed to ensure that mental 
healthcare workers have the 
knowledge and skills necessary to 
identify schizophrenic patients with 
the metabolic syndrome. 
3. The close collaboration between 
mental healthcare workers and other 
physicians is needed to establish 
better health-care for patients with 
schizophrenia. 
4. Finally, use of anti-psychotics with 
lesser metabolic side effects is needed 
in patients at risk of developing MS.
101
References
1. Lee J. et al. Metabolic Syndrome in 
Schizophrenia. Annals Academy of 
Medicine 2012; 41(10): 457-462.
2. Meyer JM, Stahl SM. The metabolic 
syndrome and schizophrenia. Acta 
Psychiatr Scand 2009; 119:4-14.
3. Osborn DP, Levy G, Nazareth I, 
Petersen I, Islam A, King MB. Relative 
risk of cardiovascular and cancer 
mortality in people with severe mental 
illness from the United Kingdom‘s 
General Practice Research Database. 
Arch Gen Psychiatry 2007; 64:242-9.
4. Lin PI, Shuldiner AR. Rethinking 
the genetic basis for comorbidity of 
schizophrenia and type 2 diabetes. 
Schizophr Res 2010; 123:234-43.
5. Mc Creadie RG, Scottish Schizophrenia 
Lifestyle G. Diet, smoking and 
cardiovascular risk in people with 
schizophrenia: descriptive study. Br J 
Psychiatry 2003; 183:534-9.
6. Martynikhin I, Tanyanskiy D, Rotar 
O, Solntsev V, Sokolian N, et al. 
Schizophrenia and risk of metabolic 
syndrome. Archives of Psychiatry and 
Psychotherapy 2013; 2: 15–20.
7. Brown S, Kim M, Mitchell C, Inskip 
H. Twenty-five year mortality of a 
community cohort with schizophrenia. 
Br J Psychiatry 2010; 196: 116–121.
8. Osby U, Correia N, Brandt L, Ekbom 
A, Sparen P. Mortality and causes of 
death in schizophrenia in Stockholm 
county, Sweden. Schizophr Res 2000; 
45: 21–28.
9. Laursen TM. Life expectancy among 
persons with schizophrenia of bipolar 
affective disorder. Schizophr Res 2011; 
131: 101–104.
10. Mc Evoy JP, Meyer JM, Goff DC, 
Nasrallah HA, Davis SM, Sullivan L, 
et al. Prevalence of the metabolic 
syndrome in patients with 
schizophrenia: baseline results from 
the Clinical Antipsychotic Trials of 
Intervention Effectiveness (CATIE) 
schizophrenia trial and comparison 
with national estimates from NHANES 
III. Schizophr Res 2005;80:19–2.
11. Ford ES, Giles WH, Dietz WH. 
Prevalence of the metabolic syndrome 
among US adults: findings from the 
third National Health and Nutrition 
Examination Survey. JAMA 2002; 
287:356–359.
12. Heiskanen T, Niskanen L, Lyytikainen, 
R, Saarinen PI, Hintikka J. Metabolic 
syndrome in patients with 
schizophrenia. J Clin Psychiatry 2003; 
64: 575–579.
13.  Cohn T, Prud’homme D, Streiner D, 
Kameh H, Remington G. Characterizing 
coronary heart disease risk in chronic 
schizophrenia: High Prevalence of the 
Metabolic Syndrome. Can J Psychiatry 
2004; 49: 753–760.
14. De Hert M, van Winkel R, Van Eyck 
D, Hanssens L, Wampers M, Scheen 
A, et al. Prevalence of diabetes, 
metabolic syndrome and metabolic 
abnormalities in schizophrenia over 
the course of the illness: a cross-
sectional study. Clin Pract Epidemiol 
Ment Health. 2006; 2: 14.
15. Bobes J, Arango C, Aranda P, Carmena 
R, Garcia-Garcia M, CLAMORS 
Study Collaborative Group, et al. 
Cardiovascular and metabolic risk 
in outpatients with schizophrenia 
treated with antipsychotics: results of 
the CLAMORS Study. Schizophr Res 
2007; 90:162-73.
16. De Hert M, Schreurs V, Sweers K, Van 
Eyck D, Hanssens L, Sinko S,et al. 
Typical and atypical antipsychotics 
differentially affect long-term 
incidence rates of the metabolic 
syndrome in first-episode patients 
with schizophrenia: a retrospective 
chart review. Schizophr Res 2008; 
101:295-303.
17. Huang MC, Lu ML, Tsai CJ, Chen PY, 
Chiu CC, Jian DL, et al. Prevalence of 
metabolic syndrome among patients 
with schizophrenia or schizoaffective 
disorder in Taiwan. Acta Psychiatr 
Scand 2009; 120:274-80.
18. Koponen HJ, Hakko HH, Saari 
KM, Lindeman SM, Karvonen KM, 
Isohanni MK, et al. The prevalence 
and predictive value of individual 
criteria for metabolic syndrome in 
Vol.11 No.1 2019
102
schizophrenia: a Northern Finland 
1966 Birth Cohort Study. World J Biol 
Psychiatry 2010; 11:262-7.
19. Sugawara N, Yasui-Furukori N, Sato Y, 
Umeda T, Kishida I, Yamashita H, et 
al. Prevalence of metabolic syndrome 
among patients with schizophrenia in 
Japan. Schizophr Res 2010; 123:244-50.
20. Saddichha S, Manjunatha N, Ameen S, 
Akhtar S. Metabolic syndrome in first 
episode schizophrenia - a randomized 
double-blind controlled, short-term 
prospective study. Schizophr Res 
2008; 101:266-72.
21. Schorr SG, Slooff CJ, Bruggeman R, 
Taxis K. The incidence of metabolic 
syndrome and its reversal in a cohort 
of schizophrenic patients followed for 
one year. J Psychiatr Res 2009; 43:1106-
11.
22. Tirupati S, Chua LE. Body mass index 
as a screening test for metabolic 
syndrome in schizophrenia and 
schizoaffective disorders. Australas 
Psychiatry 2007;15:470-3.
23. Mousa FA, Dessoki HH, El Kateb 
SM, Ezzat AA, Soltan MR. Metabolic 
syndrome in psychiatric patients 
(comparative study). Egyptian Journal 
of Psychiatry 2017; 38:179-191
24.   Jakovljević M, Crncević Z, Ljubicić 
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